Executive Masterclass 2 - Direct to Patient, Redefined: Pharma’s Next Commercial Frontier

Direct-to-patient is no longer a channel experiment — it is fast becoming a core commercial capability. As digital platforms, AI-driven engagement, and real-world data reshape how patients discover, access, and stay on therapy, pharma leaders are under pressure to rethink not just marketing, but the entire commercial operating model.

As the second event in our Executive Masterclass series, this exclusive, member-only session convenes senior pharma executives and investment leaders for a candid discussion on how direct-to-patient strategies are redefining growth, data ownership, and patient relationships. Panelists will explore how leaders decide where to play in the D2C landscape, how to scale responsibly within regulatory and trust constraints, and how to connect patient experience to measurable business and clinical outcomes.

Designed for senior decision-makers, the conversation offers a clear view of what it takes to build compliant, high-trust patient ecosystems in a world where the lines between pharma, retail, and technology are rapidly blurring.

Join us to discuss:

• How pharma leaders are reimagining commercial strategy in the direct-to-patient era — and where they are choosing to invest.

• How data, AI, and digital platforms are reshaping access, adherence, and lifetime patient value.

• What governance, compliance, and operating models are required to scale D2C while maintaining trust and regulatory rigor.

• How boardroom growth expectations intersect with real-world execution across brand, channel, and patient experience.